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Introduction
============

Prevention of the common[@ref1] and costly[@ref2] public health problem of osteoporosis is of great importance. Low bone mineral density is a major risk factor for osteoporotic fracture.[@ref3] Peak bone mass and rate of bone loss both impact on bone mineral density in later life[@ref4] and are equally important risk factors for osteoporotic fracture.[@ref5] A 10% increase in peak bone mass is estimated to halve the risk of an osteoporotic fracture in adult life.[@ref6] Low bone mineral density is also a risk factor for fracture in childhood.[@ref7] [@ref8] [@ref9] Strategies to maximise peak bone mass in children have been identified as a priority area for research.[@ref10]

One such potential strategy is to improve vitamin D levels in children. Vitamin D deficiency is diagnosed by measurement of serum 25-hydroxyvitamin D.[@ref11] Concentrations above 50 nmol/L are considered normal, but there is debate about the level of this threshold[@ref12] because although only lower levels are usually associated with clinical disease such as rickets, the optimal level for bone health may be above 50 nmol/L. A low vitamin D level in children and adolescents is common enough to be an important public health issue globally across a range of latitudes, including the United Kingdom,[@ref13] [@ref14] other European countries,[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] the United States,[@ref21] Lebanon,[@ref22] Australia,[@ref23] [@ref24] and New Zealand.[@ref11] [@ref25] [@ref26] Overt vitamin D deficiency leads to rickets, and subclinical vitamin D deficiency may also affect bone mineralisation, as assessed by dual x ray absorptiometry.[@ref15] [@ref17] [@ref27] [@ref28] [@ref29] Randomised controlled trials of vitamin D supplementation have, however, reported inconsistent results for bone densitometry measures,[@ref27] [@ref30] [@ref31] [@ref32] [@ref33] [@ref34] and therefore the effectiveness of vitamin D supplementation for improving bone density is unclear.

With this systematic review we aimed to determine the effectiveness of vitamin D supplementation for improving bone density in healthy children and adolescents, to identify factors modifying any effect, and to determine if any effect persists after supplementation ceases.

Methods
=======

The protocol for this review is published elsewhere.[@ref35] Studies were eligible for inclusion if they were randomised placebo controlled trials of at least three months of vitamin D supplementation, were carried out in healthy children or adolescents aged between 1 month and 20 years, and measured primary outcomes of areal or volumetric bone mineral density, bone mineral content, or quantitative ultrasound measures (broadband ultrasound attenuation, speed of sound, stiffness index).

Although fractures in later life would be the ideal outcome measure, this would require following large numbers of children as participants for decades. No such studies have been done, so we used bone density measures as surrogate outcomes, as is commonly seen in children.[@ref36] Bone mineral density and content[@ref7] [@ref8] [@ref9] and quantitative ultrasound measures[@ref37] have all been associated with fracture risk.

Identification of studies
-------------------------

The electronic literature search was last updated on 9 August 2009. Without language restrictions, we searched the Cochrane Central Register of Controlled Trials, Medline (1966 to present), Embase (1980 to present), CINAHL (1982 to present), AMED (1985 to present), and ISI Web of Science (1945 to present). Web extra appendix 1 gives the search strategy used for Medline, which was adapted as appropriate for other databases.

We hand searched conference abstract issues of key journals for 2007-8: *Osteoporosis International*, *Journal of Bone and Mineral Research*, *Asia Pacific Journal of Clinical Nutrition*, *Journal of the American Dietetic Association*, *Proceedings of the Nutrition Society*, *Journal of Nutrition*. We examined the reference lists and ISI citations of all included studies. Two reviewers assessed potentially relevant articles against the inclusion criteria.

Data collection and analysis
----------------------------

Two reviewers independently extracted data. We extracted change in bone mineral density and bone mineral content as percentage change from baseline, as well as sex, age, pubertal stage, baseline serum vitamin D levels, ethnicity, type and dose of vitamin D given, and compliance as possible effect modifiers, along with data on adverse events. No studies reported quantitative ultrasound outcomes. Two reviewers independently assessed each trial's risk of bias, assessing factors such as randomisation, allocation concealment, blinding, completeness of outcome assessment, and selective reporting. Where necessary we contacted authors to obtain information on primary outcome factors.

We converted bone density outcomes to standardised mean differences, calculating a standardised mean difference of the percentage change from baseline in treatment and control groups at each site for which there were sufficient data (bone mineral density for forearm, hip, and lumbar spine and total body bone mineral content). Where clinically useful, we estimated a benefit in units of percentage change since baseline from the standardised mean differences by estimating the pooled standard deviation from the means of the standard deviation of the outcomes in treatment and control groups for each study, and multiplying the standardised mean differences by this.[@ref38] [@ref39] [@ref40]

We calculated statistical heterogeneity using a χ^2^ test on N-1 degrees of freedom, with significance conservatively set at 0.10. We also assessed inconsistency I^2^ using the formula \[(Q-df)/Q\]×100%, where Q is the χ^2^ statistic and df is its degrees of freedom, to describe the percentage of the variability in effect estimates due to heterogeneity. We considered a value greater than 50% as denoting substantial heterogeneity.

Meta-analysis was done according to a fixed effects model. When heterogeneity was considered substantial, we explored its causes by carrying out prespecified subgroup analyses where data were available---that is, subgroups by sex, pubertal stage, dose of vitamin D, baseline vitamin D levels, compliance, and adequacy of allocation concealment. Data were insufficient to consider ethnicity and sun exposure as possible sources of heterogeneity, as planned in the original protocol. Where there were not clear clinical reasons or study methodology reasons for substantial heterogeneity between studies, we proceeded to meta-analysis using random effects models. All analyses were carried out in Review Manager 5 (version 5.0.16).

We performed a priori subgroup analyses by sex, pubertal stage, dose of vitamin D, and baseline vitamin D levels to determine whether the effects of supplementation varied by these factors. As the numbers of studies were small, the cut-offs of 200 IU for vitamin D dose and 35 nmol/L for baseline vitamin D concentrations were chosen on the basis of their being sufficient data available at these cut-offs to allow for subgroup analyses. When possible we used intention to treat data in analyses, but if these were not available we used, in order of preference, data from available data or per protocol analyses. Assessment of publication bias was by funnel plot.

Where studies had more than one vitamin D dosage group, we combined the data from all dosage groups and compared this with placebo. The exception to this was in subgroup analyses by vitamin D dose---for those studies with a dosage group falling into each subgroup we used the data from the individual dosage group for the treatment arms and used the control group mean and standard deviation for each subgroup comparison but reduced the number in the control groups by half for each comparison.

One study was a cluster randomised controlled trial,[@ref32] with data that did not account for clustering. We used the subsequently published intracluster correlation for total body bone mineral content[@ref41] in a sensitivity analysis, correcting the sample size for the effect of clustering by the design effect of 1.946, calculated by 1+(M−1)ICC, where M is the cluster size and ICC the intracluster correlation (87 and 0.011, respectively).

Results
=======

The search identified 1653 references, of which 1599 were excluded at initial independent screening of the title and abstract (κ=0.66), with 25 disagreements. The disagreements were resolved by consensus and all 25 were excluded at screening of the abstract. Six references were in German. These were excluded after assessment by a rheumatologist fluent in German in conjunction with one author.

Of the 23 references requiring full text review, 12 references to seven studies were included (see web extra appendix 2). Studies were excluded for several reasons: not randomised controlled trials (four studies),[@ref42] [@ref43] [@ref44] [@ref45] participants not within age range 1 month to 20 years (three studies),[@ref46] [@ref47] [@ref48] bone density outcomes not measured (two studies),[@ref49] [@ref50] no vitamin D intervention (one study),[@ref51] and not placebo controlled trial(one study).[@ref16] One study was excluded for not reporting a variance measure.[@ref30] This study was small (n=60) and reported no effect of supplementation for bone mineral content at the distal one third of the radius.

The meta-analysis used data from six studies, with 343 participants receiving placebo and 541 receiving vitamin D (table 1[](#tbl1){ref-type="table"}).[@ref27] [@ref31] [@ref32] [@ref33] [@ref34] [@ref52] The full review provides more detailed information on these studies.[@ref54] Participants were aged from 8 to 17 years. Bone density was measured by dual x ray absorptiometry in all studies except one in which volumetric bone mineral density was measured using peripheral quantitative computed tomography at the distal radius.[@ref27] No studies measured quantitative ultrasound outcomes. All studies administered vitamin D~3~ (cholecalciferol), with the dose ranging from 132 IU daily[@ref32] to 14 000 IU per week[@ref31] [@ref33] over one[@ref31] [@ref33] [@ref34] [@ref52] or two[@ref27] [@ref32] years. One study provided follow-up data for three years after supplementation.[@ref32] Two studies included cointerventions, one of milk, providing an average of 245 mg/day of calcium to both control and supplement groups,[@ref32] and one of 1000 mg/day of calcium carbonate in both vitamin D and control groups.[@ref27] Mean baseline serum vitamin D levels ranged from 17.7 to 49.5 nmol/L. Results from available data analysis were extracted for all studies except one,[@ref32] which reported per protocol analysis, excluding 33 participants with poor compliance.

###### 

 Characteristics of studies included in meta-analysis

  Study                            Cholecalciferol dose             Duration (years)   No    Ethnicity   Pubertal stage   Female (%)   Mean (range) age (years)   Baseline serum vitamin D level (nmol/L)   Site measured\*
  -------------------------------- -------------------------------- ------------------ ----- ----------- ---------------- ------------ -------------------------- ----------------------------------------- -------------------------------------------
  Andersen 2008^52^                400 or 200 IU/day                1                  26    Pakistani   NS               100          12.2† (10.1-14.7)          7.3-16.9                                  Lumbar spine, total body
  Cheng 2005^27^                   200 IU/day                       2                  98    White       Prepubertal      100          11.1 (10-12)               49.5                                      Hip, lumbar spine, total body
  Du 2004^32^                      132 IU/day                       2                  498   Chinese     Mixed            100          10.1 (NS)                  17.7-20.6                                 Forearm, total body
  El Hajj Fuleihan 2006^33\ 54^:                                                                                                                                                                            
   Males                           1400 IU/week or 14 000 IU/week   1                  184   NS          Mixed            0            13.0 (10-17)               40                                        Lumbar spine, hip, 1/3 radius, total body
   Females                         1400 IU/week or 14 000 IU/week   1                  179   NS          Mixed            100          13.2 (10-17)               34.9                                      Lumbar spine, hip, 1/3 radius, total body
  Viljakainen 2006^34^             400 or 200 IU/day                1                  228   White                        100          11.4 (11-12)               47                                        Lumbar spine, hip

NS=Not specified.

\*Further details of measures in Cochrane review.^53^

†Median.

Risk of bias
------------

One study had clearly documented and adequate sequence generation, allocation concealment, blinding, and reasons for withdrawals.[@ref27] Two other studies described adequate sequence generation and allocation concealment,[@ref31] [@ref33] [@ref54] and in the remaining three studies these were unclear.[@ref32] [@ref34] [@ref52] All studies were stated to be double blind, although the blinding process was not fully described. The risk of bias from this was, however, assessed as very low as it is unlikely that bone density outcomes could be influenced by lack of blinding. No study reported imputing for missing data in the analysis, but loss to follow-up was for the most part either evenly distributed across groups[@ref31] [@ref33] [@ref52] [@ref54] or reasons for withdrawal were stated and unlikely to be related to the true outcome.[@ref27] [@ref34] Incomplete outcome data posed a risk of bias in one study in which forearm bone mineral density was measured but not reported.[@ref32]

Although the number of studies was small, funnel plots suggested that publication bias was not present (data not shown, see full review for details[@ref53]).

Effects of interventions
------------------------

Table 2[](#tbl2){ref-type="table"} gives the main effects of vitamin D supplementation at different sites (see also figure[](#fig1){ref-type="fig"}). Overall, vitamin D supplementation did not have statistically significant effects on percentage change in total body bone mineral content or bone mineral density of the hip or forearm. There was a trend to a small effect on lumbar spine bone mineral density (standardised mean difference 0.15, 95% confidence interval −0.01 to 0.31, P=0.07). The results for percentage change were statistically heterogeneous for bone mineral density of the hip (χ^2^=6.09, df=3, P=0.11, I^2^=51%) and forearm (χ^2^=7.82, df=2, P=0.02, I^2^=74%) but not at other sites. The use of data on total body bone mineral content corrected for cluster effects[@ref32] [@ref41] did not materially affect the result (total body bone mineral content standardised mean difference 0.09, −0.08 to 0.26).

![Forest plots of main effects of vitamin D supplementation on bone mineral density of hip, lumbar spine, and forearm, and total body bone mineral content. M=males; F=females. \*Fixed model used for lumbar spine bone mineral density and total body bone mineral content. See web extra for data to two decimal places](wint804930.f1_default){#fig1}

###### 

 Main effects of vitamin D supplementation

  Outcome                             No of studies   No of participants   Standardised mean difference\* (95% CI)
  ----------------------------------- --------------- -------------------- -----------------------------------------
  Hip bone mineral density            4               639                  0.06 (−0.18 to 0.29)
  Lumbar spine bone mineral density   5               660                  0.15 (−0.01 to 0.31)†
  Total body bone mineral content     5               672                  0.10 (−0.06 to 0.26)
  Forearm bone mineral density        3               563                  0.04 (−0.36 to 0.45)

Outcome is percentage change from baseline.

\*Standardised mean difference of 0.3 regarded as small.^59^

†P=0.07.

Heterogeneity
-------------

Sex, baseline serum vitamin D level, and adequacy of allocation concealment did not explain heterogeneity seen between studies for analyses of hip and forearm bone mineral density. One study comprised males only. Heterogeneity was still significant in studies in females (hip: χ^2^=4.94, df=2, P=0.08, I^2^=60%; forearm: χ^2^=4.32, df=1, P=0.04, I^2^=60%). One study with outcomes for hip and forearm bone mineral density comprised participants with a mean baseline serum vitamin D concentration less than 35 nmol/L. Significant heterogeneity remained in those studies with participants who had a baseline serum vitamin D concentration above this level (hip: χ^2^=4.54, df=2, P=0.10, I^2^=56%; forearm: χ^2^=7.66, df=1, P=0.006, I^2^=87%). In subgroup analysis by allocation concealment (adequate compared with inadequate or unclear) heterogeneity remained in the adequate allocation concealment subgroup for hip bone mineral density (χ^2^=4.47, df=2, P=0.11, I^2^=55%). No studies had inadequate or unclear allocation concealment for forearm bone mineral density, so subgroup analysis could not be done.

Classification of studies into subgroups by compliance and by pubertal status of participants in the study as a whole resulted in identical subgroups. Only one study was in purely prepubertal children,[@ref27] and this was the only study with low compliance. All other studies were in children and adolescents of mixed pubertal status with high compliance. In the mixed pubertal stage and high compliance subgroup, heterogeneity was not significant at either the hip or the forearm (χ^2^=2.55, df=2, P=0.28, I^2^=22%; and χ^2^=0.64, df=1, P=0.42, I^2^=0%).

Subgroup analyses for differences in effects
--------------------------------------------

The effects of supplementation at all sites were similar regardless of vitamin D dose given (\>200 IU daily *v* ≤200 IU daily; data not shown, see full Cochrane review for details[@ref54]) and sex (table 3[](#tbl3){ref-type="table"}). In females but not in males, however, the effect on lumbar spine bone mineral density was statistically significant. There was a trend for larger effect in the low serum vitamin D subgroup of studies for total body bone mineral content (P=0.09 for subgroup difference), but effects were similar between low and high serum vitamin D groups at other sites (table 4[](#tbl4){ref-type="table"}). In the low serum vitamin D studies, however, the effect for total body bone mineral content was significant (P=0.04), and the result for lumbar spine bone mineral density bordered on significance (P=0.05).

###### 

 Subgroup analyses of effects of vitamin D supplementation by sex

  Outcome                             Females   Males                                    
  ----------------------------------- --------- ------- ---------------------- --- ----- -----------------------
  Hip bone mineral density            3         467     0.09 (−0.21 to 0.40)   1   172   −0.07 (−0.39 to 0.25)
  Lumbar spine bone mineral density   4         488     0.20 (0.01 to 0.39)†   1   172   0.01 (−0.31 to 0.33)
  Total body bone mineral content     4         500     0.13 (−0.05 to 0.31)   1   172   0.01 (−0.31 to 0.33)
  Forearm bone mineral density        2         255     0.20 (−0.35 to 0.76)   1   172   −0.25 (−0.57 to 0.07)

Outcome is percentage change from baseline.

\*Standardised mean difference of 0.3 regarded as small.^59^

†Statistically significant at 5% level.

###### 

 Subgroup analyses of effects of vitamin D supplementation by baseline serum vitamin D level

  Outcome                             Low baseline vitamin D level (\<35 nmol/L)   High baseline vitamin D level (≥35 nmol/L)                                     
  ----------------------------------- -------------------------------------------- -------------------------------------------- ----------------------- --- ----- ------------------------
  Hip bone mineral density            1                                            168                                          0.25 (−0.07 to 0.58)    3   471   −0.02 (−0.31 to 0.28)
  Lumbar spine bone mineral density   2                                            189                                          0.31 (0.00 to 0.61)†    3   471   0.09 (−0.10 to 0.28)
  Total body bone mineral content     3                                            413                                          0.21 (0.01 to 0.41)‡    2   259   −0.07 (−0.33 to 0.18)§
  Forearm bone mineral density        1                                            168                                          −0.06 (−0.38 to 0.26)   2   259   0.12 (−0.62 to 0.85)

Outcome is percentage change from baseline.

\*Standardised mean difference of 0.3 regarded as small.^59^

†P=0.05.

‡Statistically significant at 5% level.

§P=0.09 for difference.

Vitamin D supplementation had a greater effect for forearm bone mineral density in studies in prepubertal and low compliance children (table 5[](#tbl5){ref-type="table"}) but the direction of this effect was the opposite of that observed at other sites. We also compared effects in prepubertal (Tanner stage 1 or 2) and postpubertal (Tanner stage 3 and 4) young people derived from within individual studies. These did not show any significant differences in effects between groups at any site (table 6[](#tbl6){ref-type="table"}).

###### 

 Subgroup analyses of effects of vitamin D supplementation by pubertal status and compliance

  Outcome                             Prepubertal and low compliance   Mixed pubertal and high compliance                                     
  ----------------------------------- -------------------------------- ------------------------------------ ----------------------- --- ----- -----------------------
  Hip bone mineral density            1                                87                                   −0.30 (−0.72 to 0.13)   3   552   0.14 (−0.3 to 0.32)
  Lumbar spine bone mineral density   1                                87                                   −0.19 (−0.61 to 0.23)   4   573   0.21 (0.04 to 0.38)†‡
  Total body bone mineral content     1                                87                                   −0.22 (−0.64 to 0.20)   4   585   0.15 (−0.02 to 0.32)
  Forearm bone mineral density        1                                87                                   0.51 (0.08 to 0.93)†    2   340   −0.16 (−0.38 to 0.07)

Outcome is percentage change from baseline.

\*Standardised mean difference of 0.3 regarded as small.^59^

†Statistically significant at 5% level.

‡P=0.09 for difference.

###### 

 Subgroup analyses of effects of vitamin D supplementation by pubertal status

  Outcome                             Prepubertal (Tanner stage 1 or 2)   Postpubertal (Tanner stage 3 or 4)                                     
  ----------------------------------- ----------------------------------- ------------------------------------ ----------------------- --- ----- ----------------------
  Hip bone mineral density            4                                   335                                  0.00 (−0.36 to 0.37)    3   304   0.17 (−0.07 to 0.40)
  Lumbar spine bone mineral density   4                                   335                                  0.01 (−0.22 to 0.24)    3   304   0.16 (−0.07 to 0.40)
  Total body bone mineral content     4                                   318                                  −0.01 (−0.24 to 0.22)   3   325   0.18 (−0.05 to 0.40)
  Forearm bone mineral density        3                                   213                                  0.13 (−0.45 to 0.72)    2   214   0.06 (−0.23 to 0.34)

Outcome is percentage change from baseline.

\*Where total number of studies compared exceeds six, studies contribute data to more than one subgroup.

†Standardised mean difference of 0.3 is regarded as small.^59^

Sensitivity analyses
--------------------

Correcting for intracluster correlation in one study did not materially affect the results for total body bone mineral content (data not shown).[@ref32] In light of the findings about the explanatory effect for heterogeneity in Cheng 2005,[@ref27] subgroup analyses were repeated by sex, baseline serum vitamin D level, dose of cholecalciferol, and adequacy of allocation concealment, omitting this study where there was heterogeneity within any subgroup. This was possible only for hip bone mineral density owing to the number of studies involved. This reduced heterogeneity to non-significant levels. An effect on hip bone mineral density in females was found (standardised mean difference 0.24, 95% confidence interval 0.03 to 0.45, P=0.03), which was not seen when Cheng 2005 was included, but the effect size was still similar in both sexes. Results of analyses for hip bone mineral density by serum vitamin D level, dose of cholecalciferol, and allocation concealment were similar to those of the analyses including Cheng 2005 (data not shown).

Benefits after supplementation ceases
-------------------------------------

One study[@ref32] [@ref55] provided follow-up data after supplementation ceased. Total body bone mineral content between the group receiving calcium supplemented milk and the group receiving calcium and vitamin D supplemented milk did not differ significantly three years after supplementation ceased (percentage change since baseline 71.9 (SD 1.5) and 70.8 (SD 1.5), respectively).

Adverse events
--------------

Reporting of adverse events was limited but suggested that vitamin D supplementation is well tolerated. No children developed hypercalcaemia in one study.[@ref52] In another study, four children dropped out through disease onset described as unrelated to the trial, but gave no further details.[@ref27] In another, one child withdrew owing to skin allergy, but the intervention arm to which the child belonged and potential relationship to vitamin D was not reported.[@ref32] One study reported that treatment was well tolerated,[@ref33] with two participants in the placebo group having increased serum calcium levels at the end of one year, and one girl who received cholecalciferol 1400 IU/week developing post-streptococcal glomerulonephritis. In boys, three participants in the placebo group and one in each vitamin dose group had increased serum calcium levels at one year.[@ref33] [@ref54] The final study reported that 16 children dropped out for reasons not related to the study protocol, but gave no further details.[@ref34]

Discussion
==========

This systematic review indicates that targeting children and adolescents with low serum vitamin D concentrations could result in clinically important improvements in bone density but that vitamin D supplementation in healthy children and adolescents generally to improve bone density is not justified.

Clinical and policy implications
--------------------------------

Although it is difficult to extrapolate bone density outcomes in childhood to reduction in risk of fracture in adulthood, our results suggest that it is plausible that vitamin D supplementation in deficient children and adolescents can deliver clinically significant improvements in bone health. For example, the magnitude of the standardised mean differences of effects in children and adolescents with low baseline serum vitamin D concentrations were 0.21 for total body bone mineral content, 0.31 for lumbar spine bone mineral density, and 0.25 for hip bone mineral density, all of which were at least 0.2 standardised mean differences higher than in children and adolescents with high baseline vitamin D levels. This standardised mean difference is about equivalent to a 2.6% point greater change in total body bone mineral content from baseline in the vitamin D supplemented group than in the control group. Equivalent estimates were 1% for hip bone mineral density and 1.7% for lumbar spine bone mineral density. Effects at the forearm were neither statistically nor clinically significant. The available studies did not allow us to ascertain whether the effects of supplementation accumulate while supplementation continues or if the effect plateaus over time. However, if a 10% increase in peak bone mass can, as postulated, reduce the risk of an osteoporotic fracture in adult life by 50%,[@ref6] an effect on fracture risk in later life of both clinical and public health significance is achievable, particularly if effects do accumulate. Children with wrist and forearm fractures have a bone mineral density up to 8% lower than children without such fractures.[@ref7] [@ref8] [@ref9] We estimate that a 5% increase in total body bone mineral density and bone mineral density of the hip or lumbar spine could decrease the relative risk of fracture in childhood by about 17% and 9%, respectively.[@ref9] Thus, vitamin D supplementation has the potential to have a substantial effect on adult fracture rates and an effect in childhood.

In light of these data, the approach to addressing vitamin D deficiency in children and adolescents warrants further consideration. Possible choices include fortification of food or direct supplementation at either population or individual level. In trials of increasing vitamin D intake in children, whether through fortification of food or supplements, it is possible to achieve increases in serum vitamin D levels, but the doses of cholecalciferol required to correct deficiency and reach post-intervention vitamin D concentrations above 50 nmol/L are in excess of 400 IU/day.[@ref56] Thus, while food fortification may offer some protection against vitamin D deficiency in children,[@ref57] it is unlikely a sufficient dose could be delivered to achieve adequate serum levels in children with deficiency. Unfortunately, the alternative of screening for vitamin D deficiency and then correcting it is more costly and relatively invasive. The cost effectiveness and acceptability of screening remains to be established, including carrying out further randomised controlled trials to assess the benefits of doing so for bone health.

Potential effect modifiers
--------------------------

Besides baseline serum vitamin D levels, other potential modifiers of the effect of vitamin D supplementation include sex, pubertal status, and compliance, although the paucity of evidence available to examine potential effect modification means that definitive conclusions cannot be drawn. Based on the current evidence, it may be that vitamin D deficient females are the subgroup likely to have the greatest response to supplementation, but the paucity of data in males means that this is not certain. The average baseline vitamin D concentration in males was 5 nmol/L lower than that of females, which could contribute to any difference. Unfortunately, studies of subgroups of prepubertal compared with mixed pubertal stages and those of low and high compliance were identical, making it difficult to separate effects of these factors. However, when participants were divided within studies into prepubertal (Tanner stage 1 or 2) and postpubertal (Tanner stage 3 or 4) groups, the effects between subgroups did not differ, suggesting that compliance, rather than pubertal stage, is more likely to be an effect modifier. The direction of effect was inconsistent at the forearm compared with other sites in the analysis by pubertal status and compliance subgroups. For forearm bone mineral density the overall effect was 0.67, favouring the control group in the prepubertal and low compliance study[@ref27] but the direction of effects favoured vitamin D supplementation at the hip, lumbar spine, and total body bone mineral content. This could reflect genuine differences in the response of cortical bone (predominates at distal third of radius) compared with trabecular bone (predominates at lumbar spine, femoral neck, and total body bone mineral content). However, it is unclear why the control group would show an effect at any site. The available data do not allow this to be adequately addressed, and caution is needed in interpreting this analysis.

Limitations of the review
-------------------------

The number of studies contributing substantial data to the meta-analysis was small.[@ref27] [@ref31] [@ref32] [@ref33] [@ref34] We therefore could not fully assess the effects of important clinical factors that might influence outcomes of supplementation. For example, we could not examine the interplay between compliance, dose of cholecalciferol, and baseline vitamin D levels. This interplay might have been able to explain the lack of any difference in effect by dose should the data have allowed this to be examined. We could not adequately investigate sex differences, and data were too few to assess effects after supplementation ceased. The cut-off of 35 nmol/L to define low serum vitamin D concentration in subgroup analyses was arbitrarily chosen based on the distribution of data, so as to enable subgroup analyses. The main study contributing data to the subgroup with low baseline vitamin D level, however, included around 20% of participants with concentrations above 50 nmol/L. The effect sizes we found may therefore underestimate the benefits of supplementation in deficient children and adolescents. Further randomised controlled trials are needed to determine the maximum benefit obtainable by supplementing vitamin D deficient children and adolescents, whether benefits accrue with increasing duration of supplementation, below what serum vitamin D level benefits of supplementation can be seen, and whether benefits persist after supplementation ceases. The effects in children and adolescents overall at any site were not statistically significant, and the observed effect sizes were also consistently small and unlikely to be clinically significant, with standardised mean differences ranging from 0.04 to 0.15 (table 2). Although it would take a large study with a strongly positive result to cause a noticeable increase in effect size, the limited number of studies and relatively low overall numbers of participants could reduce the robustness of our findings, and as results from further studies become available it is important that this analysis is updated. It has been suggested that areal bone mineral density only partly corrects for bone size and that adjustment of bone mineral content for bone area, weight, and height is desirable.[@ref58] Only one study, however, reported any such data.[@ref34] The study's results using this outcome were consistent with the meta-analysis results, with no statistically significant effect with vitamin D supplements at either the hip or lumbar spine. Only surrogate outcomes could be used in this review because of the current lack of data on fracture outcome. In future studies consideration should therefore be given to including childhood fractures as an outcome. The use of fractures in older adult life as an outcome will, however, remain problematic owing to the lengthy follow-up periods that would be required.

Conclusion
----------

In conclusion, it is unlikely that vitamin D supplements are beneficial in children and adolescents with normal vitamin D levels. Our planned subgroup analyses by baseline serum vitamin D level suggest that vitamin D supplementation of deficient children and adolescents could result in clinically useful improvements, particularly in bone mineral density of the lumbar spine and total body bone mineral content, but this requires confirmation.

### What is already known on this topic

1.  Vitamin D deficiency is common

2.  Subclinical vitamin D deficiency in children seems detrimental to bone health

3.  The results of randomised controlled trials of vitamin D supplements in children and adolescents are inconsistent

### What this study adds

1.  Vitamin D supplements are unlikely to be beneficial in children and adolescents with normal vitamin D levels

2.  Vitamin D supplementation of deficient children and adolescents could result in clinically useful improvements in bone density but this requires confirmation in further studies targeting deficient children and adolescents

This paper is based on a Cochrane review published in the Cochrane Library 2010, Issue 10 (see [www.thecochranelibrary.com](www.thecochranelibrary.com) for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Library should be consulted for the most recent version of the review.
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